Industry news that matters to you.  Learn more

Archives for October 2011

GeneNews Announces SentinelGx Pharmacogenomic and Companion Diagnostic BloodRNA Service

GeneNews Limited, a molecular diagnostics company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced the launch of SentinelGx, a suite of pharmacogenomic and companion diagnostic BloodRNA services for drug development and personalized health management applications (“SentinelGx”). The SentinelGx services provide complete whole blood transcriptome analysis for RNA expression profiling of inflammatory pathways, immune system response and cell signaling based on the Company’s patented Sentinel Principle technology. A catalog of over 2,200 TaqMan BloodRNA Profiles is now available including pathway-specific, disease-specific and drug-specific gene signature panels clinically proven to express in whole blood. The disease-specific panels include gene signatures for numerous types of cancer, autoimmune, cardiovascular, infectious and neurological diseases. In connection with the SentinelGx launch, GeneNews also announced the appointment of Karl Wassmann to the newly created position of Executive Vice President, US Corporate Development to manage the SentinelGx services.

BG Medicine, Inc. Announces Availability of Galectin-3 Testing Through Cleveland HeartLab, Inc.

BG Medicine, Inc., a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that Cleveland HeartLab, Inc. is now offering BGM Galectin-3 testing services.

MDxHealth Epigenetic Biomarkers Show Ability to Confirm the Presence of Lung Cancer in Sputum Samples

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced the results of a study indicating that several of its epigenetic biomarkers are able to confirm the presence of non-small cell lung cancer (NSCLC) from routinely collected sputum samples of patients with stages I-IV of the disease. MDxHealth is developing a molecular diagnostic test, ConfirmMDx for Lung Cancer, to help physicians accurately assess the presence or absence of cancer genes. These important new data will be presented at the 5th EORTC – NCI – ASCO Annual Meeting on Molecular Markers in Cancer in Brussels, Belgium (October 27-29).

Call for Emerging Company Nominations for the PMWC 2012 Most Promising Company Competition

The 4th Personalized Medicine World Conference (PMWC) 2012 is calling for emerging company nominations for the PMWC 2012 Most Promising Company Competition. Even if you’re not attending the conference, you can still participate. The PMWC 2012 “Most Promising Company” Competition features selected companies who will present to ~1,000 top-tier investors, pharmaceuticals executives, healthcare professionals and more.

SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development

SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis’ drug discovery and development efforts.